biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Glioblastoma market US$4.2 billion in 2028

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 16, 2022 3:05pm

95 Views

Post# 35176551

RE:RE:Glioblastoma market US$4.2 billion in 2028

"It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum."

That's the biotech life. Certain catalysts can also lead to early value realization for shareholders. Biodexa may have an emerging compelling position in the space.

BTI has already been working on xB3-bevacizumab.
I forget how long ago but wasn't it even included in presentation in the last year with what Rathjen said was new data? Its interesting that BTI was still working on it. These margers can take some time to put together.

panobinostat, lomustine, xB3-bevacizumab

Midatech's lead drug currently in clinical trials is panobinostat and seeks to bypass the blood-brain barrier directly into the brain tumor. The current clinical trial will study panobinostat alone and in combination with lomustine. BTI has reseached xB3 with bevacizumab for this same tumor. Could these drugs together, with Midech's and BTI's delivery technology, solve the problems of previous trials?

"There are several potential reasons for the lack of activity with this combination. The dose of panobinostat used in this study was the maximum tolerated dose determined in our preliminary phase I study.19 Even though this dose is being explored in hematologic malignancies, it may be too low to achieve adequate tumor concentrations in the brain. This issue is compounded by the limited penetration of panobinostat across the blood-tumor barrier, a problem that is further exacerbated by combining it with bevacizumab, which reduces vascular permeability. In contrast, lomustine, which does penetrate the blood-tumor barrier, was successfully combined with bevacizumab for treatment of recurrent GBM.27 This difference underscores the need to combine bevacizumab with agents that have good blood-tumor barrier penetration. In addition, there are no preclinical data exploring the activity of the combination of panobinostat and bevacizumab in GBM models."

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Neuro-Oncology | Oxford Academic (oup.com)

JDavenport wrote: It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum.

Add that to the 15 years that Bioasis shareholders have....

Never mind.

jd